Reply to response to Wheatley et al., Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45: 76 We thank Madu et al 1 for their comments regarding our systematic review. 2 Their letter shows a serious lack of understanding of statistical methodology, especially in relation to meta-analysis. The expectation in a randomised trial is that the groups will be balanced because of the randomisation process; however, there is the possibility that, by chance, the groups could be imbalanced. This would not be a systematic error -i.e. a bias -but a random error. Meta-analysis of all the trials increases patient numbers and makes such a chance imbalance less likely. The supposition by Madu et al. that our results are due to chance differences between the arms in patient characteristics such as ulceration or sentinel lymph node biopsy (SLNB) positivity is entirely speculative. They provide no evidence for such an assertion. In fact the presence or absence of ulceration was recorded in 4 of the 6 trials and, as expected, the balance was remarkably similar between the narrow and wide margin arms (see Table 1 ). The validity and quality of these 6 randomised studies have until now been widely accepted by the melanoma surgical community precisely because prognostic characteristics have been well-matched. Since these same prognostic variables drive the population risk of SLNB positivity, there is no reason to believe that differences in SLNB positivity explain our findings. Moreover, if there were chance imbalances, they would be just as likely to go in the opposite direction, in which case the adverse impact of narrow surgical margins would have been underestimated. As we discuss in our paper, the misinterpretation of p-values is a major reason for the belief that narrow margins are not inferior to wider ones (a non-significant difference does not mean that there is no difference); Madu et al. fall into the same trap, whereas in fact the effects on MSS, OS and RFS are in no way inconsistent with each other despite only the first being conventionally significant.
Our data clearly show that increasing size of the surgical margin used to treat primary melanoma is associated with reduced risk of death from melanoma. As Madu et al point out, the real question is how our findings might be used. Firstly, the data are clinically relevant. They indicate that we cannot be certain that margin size has no effect on survival, and patients should be aware of this so that they can make decisions about treatment best suited to their preferences. 'Adhering to existing guidelines' should not preclude patient choice, and neither should the prior beliefs of the surgical community. Secondly, these findings should inform trial design, since otherwise an effect of margin size on melanoma survival, and the threshold for this, may well be missed. We agree that such trials should include stratification for all accepted relevant staging criteria, and this might include sentinel lymph node biopsy. 
